Cell News and Research

RSS

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

ASBMB disappointed with preliminary injunction barring stem-cell research funding

The American Society for Biochemistry and Molecular Biology expressed its disapproval and disappointment this week in response to the Aug. 23 ruling in the U.S. District Court for the District of Columbia that granted a preliminary injunction barring federal funding of embryonic stem-cell research.

3 Sep 2010

ForteBio launches Protein G biosensor for rapid detection of mammalian IgGs

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency.

3 Sep 2010

Celgene receives Paragraph IV Certification Letter on submission of ANDA for REVLIMID

Celgene Corporation today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration. The application requests authorization to manufacture and market generic versions of REVLIMID (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States.

3 Sep 2010

First Edition: September 3, 2010

Today's headlines contain reports on a new study showing that employers are shifting the increasing costs of premiums onto workers, efforts to get Congress to weigh in on the controversy about federal funding on stem cell research and the difficulty getting uninsured children enrolled in state Medicaid and CHIP programs.

3 Sep 2010

WHO revises treatment protocols for HIV patients

Prompted by clinical research into the early initiation of antiretroviral therapies for HIV performed at the GHESKIO clinic in Port-au-Prince, Haiti, the World Health Organization (WHO) has revised its treatment protocols for HIV patients.

3 Sep 2010

Cardiogenesis Corporation releases comment on STAR-heart study

Cardiogenesis Corporation, released comments today regarding the STAR-heart study.The STAR-heart study, which was presented at the European Society of Cardiology 2010 Congress in August 2010, reported that the intracoronary injection of autologous stem cells derived from bone marrow is associated with improved hemodynamics and long term survival in the treatment of chronic heart failure.

3 Sep 2010

Researchers find role of Vpr protein in HIV infection

Dr. Éric A. Cohen, Director of the Human Retrovirology research unit at the Institut de recherches cliniques de Montréal (IRCM), and his team published yesterday, in the online open-access journal PLos Pathogens, the results of their most recent research on the role of the Vpr protein in HIV (human immunodeficiency virus) infection and AIDS (acquired autoimmune deficiency syndrome).

3 Sep 2010

New peer-reviewed study on chemopreventive effects of Protandim

LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.

3 Sep 2010

European Menopause and Andropause Society's position statements on post-reproductive health of women

Elsevier announced today the publication of four important position statements from the European Menopause and Andropause Society (EMAS) in the journal Maturitas on common management problems in the post-reproductive health of women. The statements cover the management of the menopause in the context of obesity, epilepsy, endometriosis and premature ovarian failure. Each statement has summary recommendations as a quick aid for the busy clinician.

3 Sep 2010

Counterpart of cerebral cortex discovered in marine worms

Our cerebral cortex, or pallium, is a big part of what makes us human: art, literature and science would not exist had this most fascinating part of our brain not emerged in some less intelligent ancestor in prehistoric times. But when did this occur and what were these ancestors? Unexpectedly, scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, have now discovered a true counterpart of the cerebral cortex in an invertebrate, a marine worm.

3 Sep 2010

Research on immune system can develop new therapy for inflammation, tumors

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors.

3 Sep 2010

Scientists discover how omega-3 fatty acids shut down inflammation and reverse diabetes

Fish oil is touted for its anti-inflammatory and anti-diabetic benefits, but scientist weren't sure how the omega-3 fatty acids in fish oil work. Now, according to a report in the September 3rd issue of the journal Cell, scientists have nailed how omega-3 fatty acids both shut down inflammation and reverse diabetes in obese mice.

3 Sep 2010

Millennium publishes article on MLN4924 pathway mechanism in lymphoma

Millennium, The Takeda Oncology Company today announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL).

3 Sep 2010

Research finds immune system mechanism to minimize collateral damage

A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.

3 Sep 2010

Researchers identify metabolic property of stem cells to survive in low-oxygen environments

UT Southwestern Medical Center researchers have identified unique metabolic properties that allow a specific type of stem cell in the body to survive and replicate in low-oxygen environments.

3 Sep 2010

Scientists identify thousands of proteins that play a key role in compacting DNA

Scientists have built a clearer picture of how lengthy strands of DNA are concertinaed when our cells grow and divide, in a discovery could help explain how cell renewal can go wrong.

3 Sep 2010

Study establishes critical roles for cancer-causing Myc gene in stem cell biology

Stem cells might be thought of as trunks in the tree of life. All multi-cellular organisms have them, and they can turn into a dazzling variety other cells-kidney, brain, heart or skin, for example. One class, pluripotent stem cells, has the capacity to turn into virtually any cell type in the body, making them a focal point in the development of cell therapies, the conquering of age-old diseases or even regrowing defective body parts.

3 Sep 2010

Murad launches Hydro-Dynamic Ultimate Moisture for dry, dehydrated skin

Murad, Inc. has announced the launch of Hydro-Dynamic Ultimate Moisture, an uber-rich, all purpose moisturizer that combines an extraordinarily luxurious recipe of ingredients to quench dry, dehydrated skin and restore youthful resilience and tone.

3 Sep 2010

BARDA awards contract to develop treatment for ionizing radiation exposure

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a $153 million contract to Cellerant Therapeutics, Inc. of San Carlos, Calif., to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation which can damage the body's cells - the type of radiation that would come from a nuclear blast.

3 Sep 2010